Spineway Reports H1 2026 Financial Results

Spineway, specializing in innovative spinal implants, has released its financial results for the first half of 2026, showing a modest revenue increase to €5.7 million from €5.6 million in H1 2025. While revenue saw a 3% growth, the company maintained a stable gross margin of 67%. Operating income was impacted by regulatory investments and ERP expenses, resulting in a net loss of €1.5 million, slightly up from €1.4 million the previous year.

Spineway's efforts to expand its Medical Education strategy are notable, seeking to advance the international rollout of its ESP® artificial disc product. The company bolstered its financial position by issuing straight bonds worth up to €1.5 million to support growth initiatives, including regulatory investments essential for international expansion.